Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus

▴ Bioxytran Initiates Research Collaboration with University of Georgia
Bioxytran, Inc. , a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of Georgia.

BOSTON, MA, Feb 23, 2026 - (ACN Newswire) - Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of Georgia (UGA) as part of a $100M grant to explore the efficacy of its lead drug candidate in blocking the Highly Pathogenic Avian Influenza (HPAI) H5N1 virus, commonly known as bird flu.

The collaboration follows a previously announced Non-Disclosure Agreement (NDA) signed in March 2025 and formalizes the framework for evaluating Bioxytran’s novel galectin antagonist as a potential therapeutic for infected poultry . The research is being led by Dr. Daniela Rajao DVM, MS, PhD, a renowned expert in virology and poultry medicine, College of Veterinary Medicine, Department of Population Health at UGA .

Bioxytran’s drug candidate, PHM23, utilizes a novel mechanism of action that targets galectin proteins critical to viral replication. By blocking viral spike proteins from attaching to host cells, the therapy aims to neutralize the virus and halt its spread . In vitro studies have already demonstrated the molecule's effectiveness against viruses similar to H5N1, providing a strong foundation for this new research .

"The initiation of this research with the University of Georgia, a world leader in poultry health, marks a significant milestone for Bioxytran," said David Platt, CEO of Bioxytran, Inc. "The ongoing H5N1 outbreaks present a urgent threat to the global food supply and economy, requiring immediate mass culling that results in billions of dollars in losses. We believe our galectin antagonist technology offers a promising path forward—not just for containment, but for a humane and sustainable solution to protect animal health."

The potential of this research has already garnered significant academic recognition. Following the establishment of the collaboration, UGA selected PHM23 as one of a handful of molecules to be featured in its grant submission to the U.S. Department of Agriculture’s (USDA) prestigious $100 million HPAI Poultry Innovation Grand Challenge . This inclusion underscores the scientific promise of Bioxytran’s platform in addressing one of agriculture's most pressing challenges.

Current protocols for managing bird flu outbreaks often necessitate the culling of entire flocks to prevent the virus's spread. Bioxytran’s approach could offer a more effective alternative, enable rapid containment of the virus and mitigate the devastating economic impact on farmers and consumers .

Bioxytran is actively seeking further partnerships with academic, industry, and government stakeholders to accelerate the development and deployment of PHM23 in response to this urgent global need .

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026